Drug Royalties Co. Ramps Up Issuance

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

  • 30 Nov 2012

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

DRI planned to tap the ABS market for financing in August of 2011, but shelved the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 BNP Paribas 15,256 32 17.31
2 Bank of America Merrill Lynch (BAML) 9,637 29 10.93
3 Citi 8,264 22 9.37
4 Lloyds Bank 7,329 24 8.31
5 JP Morgan 6,580 10 7.46

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 129,591.43 378 11.20%
2 Bank of America Merrill Lynch 103,666.05 302 8.96%
3 JPMorgan 101,741.96 296 8.79%
4 Wells Fargo Securities 91,373.90 263 7.89%
5 Credit Suisse 76,186.18 204 6.58%